Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High-dose 131I-MIBG Treatment Incorporated Into Tandem High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With High-risk Neuroblastoma

NCT03061656 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT03061656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03061656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High-dose 131I-MIBG Treatment Incorporated Into Tandem High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With High-risk Neuroblastoma
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2009
Completion date
December 31, 2018
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

high risk neuroblastoma